J&J, Roche, Celgene and others power new cancer-drug wave

In the world of cancer drugs, calling a new entry "the next Avastin" or "the next Gleevec" is like picking out the next Brad Pitt or the next Beyoncé. Those two treatments were among a crop of future blockbusters launched as the new millennium kicked into gear, and they're top sellers today. But that's just what the IMS Institute for Healthcare Informatics is doing in its latest report on the pharma business. Report

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.